The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|August 16, 2021
Rheumatoid Arthritis Quiz: Best of 2020
Author(s)Lana Pine
Test your knowledge of rheumatoid arthritis with our "Best of 2020" quiz!
Advertisement
Is the following statement true or false?
A high-quality diet in rheumatoid arthritis patients has been associated with lower inflammation, and reduced disease activity.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement